Economic benefits associated with treatment-free survival of immuno-oncology agents among untreated patients with intermediate/poor-risk advanced or metastatic renal cell carcinoma
Publication
, Conference
Harrison, M; Regan, M; Atkins, M; Rao, S; Yang, S; Johansen, J; Du, E; Gu, C; Fadli, E; Betts, K; McDermott, D
Published in: JOURNAL FOR IMMUNOTHERAPY OF CANCER
November 6, 2019
Duke Scholars
Published In
JOURNAL FOR IMMUNOTHERAPY OF CANCER
ISSN
2051-1426
Publication Date
November 6, 2019
Volume
7
Publisher
BMC
Related Subject Headings
- 3211 Oncology and carcinogenesis
- 3204 Immunology
Citation
APA
Chicago
ICMJE
MLA
NLM
Harrison, M., Regan, M., Atkins, M., Rao, S., Yang, S., Johansen, J., … McDermott, D. (2019). Economic benefits associated with treatment-free survival of immuno-oncology agents among untreated patients with intermediate/poor-risk advanced or metastatic renal cell carcinoma. In JOURNAL FOR IMMUNOTHERAPY OF CANCER (Vol. 7). BMC.
Harrison, Michael, Meredith Regan, Michael Atkins, Sumati Rao, Shuo Yang, Jennifer Johansen, Ella Du, et al. “Economic benefits associated with treatment-free survival of immuno-oncology agents among untreated patients with intermediate/poor-risk advanced or metastatic renal cell carcinoma.” In JOURNAL FOR IMMUNOTHERAPY OF CANCER, Vol. 7. BMC, 2019.
Harrison M, Regan M, Atkins M, Rao S, Yang S, Johansen J, et al. Economic benefits associated with treatment-free survival of immuno-oncology agents among untreated patients with intermediate/poor-risk advanced or metastatic renal cell carcinoma. In: JOURNAL FOR IMMUNOTHERAPY OF CANCER. BMC; 2019.
Harrison, Michael, et al. “Economic benefits associated with treatment-free survival of immuno-oncology agents among untreated patients with intermediate/poor-risk advanced or metastatic renal cell carcinoma.” JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. 7, BMC, 2019.
Harrison M, Regan M, Atkins M, Rao S, Yang S, Johansen J, Du E, Gu C, Fadli E, Betts K, McDermott D. Economic benefits associated with treatment-free survival of immuno-oncology agents among untreated patients with intermediate/poor-risk advanced or metastatic renal cell carcinoma. JOURNAL FOR IMMUNOTHERAPY OF CANCER. BMC; 2019.
Published In
JOURNAL FOR IMMUNOTHERAPY OF CANCER
ISSN
2051-1426
Publication Date
November 6, 2019
Volume
7
Publisher
BMC
Related Subject Headings
- 3211 Oncology and carcinogenesis
- 3204 Immunology